Patents by Inventor Mark Connors
Mark Connors has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12381514Abstract: A power management circuit supporting phase correction in an analog signal is disclosed. The power management circuit includes a power amplifier circuit configured to amplify an analog signal having a time-variant power envelope based on a modulated voltage. The power management circuit also includes an envelope tracking (ET) integrated circuit (ETIC) configured to generate the modulated voltage and a modulated phase correction voltage to thereby cause a phase change in the analog signal. In embodiments disclosed herein, a correlation between the time-variant power envelope, the modulated voltage, and the modulated phase correction voltage is explored to thereby allow the ETIC to generate the modulated voltage and the modulated phase correction voltage based on the time-variant power envelope. As a result, it is possible to enable good time and phase alignment between the modulated voltage and the time-variant power envelope to thereby improve efficiency and linearity of the power amplifier circuit.Type: GrantFiled: November 29, 2021Date of Patent: August 5, 2025Assignee: Qorvo US, Inc.Inventors: Andrew F. Folkmann, Nadim Khlat, Mark Connor
-
Publication number: 20250215068Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: ApplicationFiled: December 11, 2024Publication date: July 3, 2025Applicant: The U.S.A. as represented by the Secretary, Department of Health and Human ServicesInventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
-
Patent number: 12325734Abstract: Engineered TCR molecules specific to retroviral peptide/HLA complexes guide direct killing and/or enable robust immune responses against HIV infected cells. In a first aspect, a TCR fusion polypeptide comprises a TCR variable alpha (V?) domain, a TCR variable beta domain (V?) and a TCR constant region domain (C), wherein the TCR fusion polypeptide is specific for HIV peptides.Type: GrantFiled: January 15, 2020Date of Patent: June 10, 2025Assignees: Altor Bioscience LLC, The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Peter Rhode, Mark Connors, Stephen Migueles
-
Publication number: 20250179154Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: ApplicationFiled: January 23, 2025Publication date: June 5, 2025Applicant: The U.S.A. as represented by the Secretary, Department of Health and Human ServicesInventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
-
Patent number: 12202886Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: GrantFiled: June 30, 2022Date of Patent: January 21, 2025Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicesInventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
-
Publication number: 20240293532Abstract: A replication-competent adenovirus type 4 (Ad4) modified to express the SARS-COV-2 spike protein is described. The genome of the recombinant Ad4 is modified to have a deletion of at least a portion of the adenovirus E3 region to accommodate insertion of the spike protein coding sequence. Administration of the recombinant Ad4 to the upper respiratory tract elicits mucosal immunity, which is important for protection against SARS-COV-2 infection and for preventing transmission of the virus.Type: ApplicationFiled: January 14, 2022Publication date: September 5, 2024Applicant: The U.S.A., as Represented by The Secretary, Department of Health and Human ServicesInventor: Mark Connors
-
Patent number: 12043660Abstract: Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: GrantFiled: December 14, 2021Date of Patent: July 23, 2024Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Trustees of Columbia University in the City of New YorkInventors: Peter Kwong, Young Do Kwon, Ivelin Georgiev, Gilad Ofek, Baoshan Zhang, Krisha McKee, John Mascola, Mark Connors, Gwo-Yu Chuang, Sijy O'Dell, Robert Bailer, Mark Louder, Mangaiarkarasi Asokan, Richard Schwartz, Jonathan Cooper, Kevin Carlton, Michael Bender, Amarendra Pegu, Lawrence Shapiro, Tatyana Gindin, Lisa Kueltzo
-
Publication number: 20230060304Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: ApplicationFiled: June 30, 2022Publication date: March 2, 2023Applicant: The U.S.A, as represented by the Secretary, Department of Health and Human ServiceInventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
-
Publication number: 20220368283Abstract: A power management circuit supporting phase correction in an analog signal is disclosed. The power management circuit includes a power amplifier circuit configured to amplify an analog signal having a time-variant power envelope based on a modulated voltage. The power management circuit also includes an envelope tracking (ET) integrated circuit (ETIC) configured to generate the modulated voltage and a modulated phase correction voltage to thereby cause a phase change in the analog signal. In embodiments disclosed herein, a correlation between the time-variant power envelope, the modulated voltage, and the modulated phase correction voltage is explored to thereby allow the ETIC to generate the modulated voltage and the modulated phase correction voltage based on the time-variant power envelope. As a result, it is possible to enable good time and phase alignment between the modulated voltage and the time-variant power envelope to thereby improve efficiency and linearity of the power amplifier circuit.Type: ApplicationFiled: November 29, 2021Publication date: November 17, 2022Inventors: Andrew F. Folkmann, Nadim Khlat, Mark Connor
-
Publication number: 20220098286Abstract: Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: ApplicationFiled: December 14, 2021Publication date: March 31, 2022Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Trustees of Columbia University in the City of New YorkInventors: Peter Kwong, Young Do Kwon, Ivelin Georgiev, Gilad Ofek, Baoshan Zhang, Krisha McKee, John Mascola, Mark Connors, Gwo-Yu Chuang, Sijy O'Dell, Robert Bailer, Mark Louder, Mangaiarkarasi Asokan, Richard Schwartz, Jonathan Cooper, Kevin Carlton, Michael Bender, Amarendra Pegu, Lawrence Shapiro, Tatyana Gindin, Lisa Kueltzo
-
Patent number: 11236152Abstract: Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: GrantFiled: November 3, 2016Date of Patent: February 1, 2022Assignees: The United States of America, as represented by the Sectetary, Department of Health and Human Services, The Trustees of Columbia University in the City of New YorkInventors: Peter Kwong, Young Do Kwon, Ivelin Georgiev, Gilad Ofek, Baoshan Zhang, Krisha McKee, John Mascola, Mark Connors, Gwo-Yu Chuang, Sijy O'Dell, Robert Bailer, Mark Louder, Mangaiarkarasi Asokan, Richard Schwartz, Jonathan Cooper, Kevin Carlton, Michael Bender, Amarendra Pegu, Lawrence Shapiro, Tatyana Gindin, Lisa Kueltzo
-
Publication number: 20210324053Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: ApplicationFiled: June 25, 2021Publication date: October 21, 2021Applicant: The United States of America, as represented by the Secretary, Department of Health and HumanInventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
-
Patent number: 10815295Abstract: Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.Type: GrantFiled: July 24, 2018Date of Patent: October 27, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter D. Kwong, Gary J. Nabel, Rebecca S. Rudicell, John Mascola, Mark Connors, Ivelin Georgiev, Jiang Zhu, Young Do Kwon, Tongqing Zhou, Yongping Yang, Baoshan Zhang, Gwo-Yu Chuang, Xueling Wu, Zhi-yong Yang, Wei Shi
-
Publication number: 20200231658Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: ApplicationFiled: February 10, 2020Publication date: July 23, 2020Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
-
Patent number: 10562960Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: GrantFiled: March 18, 2016Date of Patent: February 18, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
-
Publication number: 20190077849Abstract: Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: ApplicationFiled: November 3, 2016Publication date: March 14, 2019Applicants: The Trustees of Columbia University in the City of New York, The United States of AMerica, as represented by the Secretary, Department of Health and Human SercInventors: Peter Kwong, Young Do Kwon, Ivelin Georgiev, Gilad Ofek, Baoshan Zhang, Krisha McKee, John Mascola, Mark Connors, Gwo-Yu Chuang, Sijy O'Dell, Robert Bailer, Mark Louder, Mangaiarkarasi Asokan, Richard Schwartz, Jonathan Cooper, Kevin Carlton, Michael Bender, Amarendra Pegu, Lawrence Shapiro, Tatyana Gindin, Lisa Kueltzo
-
Publication number: 20190016786Abstract: Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.Type: ApplicationFiled: July 24, 2018Publication date: January 17, 2019Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Peter D. Kwong, Gary J. Nabel, Rebecca S. Rudicell, John Mascola, Mark Connors, Ivelin Georgiev, Jiang Zhu, Young Do Kwon, Tongqing Zhou, Yongping Yang, Baoshan Zhang, Gwo-Yu Chuang, Xueling Wu, Zhi-yong Yang, Wei Shi
-
Publication number: 20180298083Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: ApplicationFiled: March 18, 2016Publication date: October 18, 2018Applicant: The United States of America, as repsented By the Secretary, Department of Health and Human ServicesInventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
-
Patent number: 10047148Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.Type: GrantFiled: September 8, 2017Date of Patent: August 14, 2018Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Mark Connors, Jinghe Huang, Leo B. Laub, Peter Kwong, Gary Nabel, John R. Mascola, Baoshan Zhang, Rebecca S. Rudicell, Ivelin Georgiev, Yongping Yang, Jiang Zhu, Gilad Ofek
-
Patent number: 10047147Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.Type: GrantFiled: August 4, 2014Date of Patent: August 14, 2018Assignee: The United States of American, as represented by the Secretary, Department of Health and Human ServicesInventors: Mark Connors, Jinghe Huang, Leo Laub, John Mascola, Nancy Longo, Nicole Doria-Rose